Payment Economics for Healthcare

Healthcare is the first vertical where Payment Yield must be measured on both sides of the ledger. Supplier payments produce yield through AP, Procurement, and Treasury. Patient and payer receivables produce yield through Revenue Cycle. A health system that measures only the pay side is measuring half of its capital architecture.

A regional health system with $1.7 billion in annual revenue and $750 million in non-labor spend allocates capital across its supplier base every day of the fiscal year, and across the patient and payer receivables that fund the same fiscal year on the other side of the ledger. Payment terms, methods, financing programs, supplier contract structure, payer contract structure, and patient collections architecture together determine whether the capital flowing through the system leaves as cost only or returns, in measurable basis points, as yield. The supplier-base measurement set the Phase 3 manufacturing work consolidated reaches half of the architecture in healthcare. Revenue Cycle holds the other half.

Healthcare proves that Payment Yield is not limited to the supplier payment file. In a health system, Treasury governs the pay side, Revenue Cycle governs the collect side, and both offices make modality decisions that determine whether capital flow exits as cost or returns as measurable yield. Payment Economics gives the CFO one reconciled line across both sides of the cash conversion cycle.

The pay-side activation in healthcare runs with structural compressions specific to the vertical: Group Purchasing Organization contracts that absorb Capital Return at the contract layer, compliance architecture that constrains the form of acceptance suppliers can offer, and multi-entity AP fragmentation that suppresses Supplier Acceptance against the consolidated ceiling. These compressions reduce the absolute dollar weight of Tier 1 activation at a representative health system. The framework reads them as architectural inputs rather than as failures of optimization.

The structural complement is collect-side. Revenue Cycle in a US health system holds modality selection authority over receivables financing, patient payment plan structure, point-of-service collections, and the integration between front-end and back-end billing. The financial accommodations Revenue Cycle authorizes (AR factoring, receivables-based financing, early-out programs, third-party patient financing) deploy capital and generate measurable economic return in the same units the pay-side instruments report. Under fragmented measurement, those returns sit on a working capital report and the supplier-side returns sit on a Payment Yield report, and the two reports rarely reconcile. Under paired measurement, both sides report into the same Payment Yield line.

Issue 23 established the Payment Yield line as a CFO-level measurement consolidating returns across AP, Treasury, and Procurement (Jasinski & Yana Mbena, 2026a). Issue 24 walked through Treasury’s modality selection authority on the pay side (Jasinski, 2026b). Issue 25 walked through Procurement’s activation at contract signing (Jasinski, 2026c). Issue 26 demonstrated the full activation surface across the manufacturer’s supplier base through the Kraljic segmentation (Jasinski, 2026d). This issue takes the health system’s perspective: the cash conversion cycle as a two-sided yield surface, with Treasury and Revenue Cycle operating as parallel modality selection authorities on opposite sides of the capital flow.

What healthcare already manages

A regional health system with $750 million in non-labor spend and $1.7 billion in annual revenue reads its financial architecture through a dense set of existing instruments. Total landed cost on the supply side runs through Procurement and the GPO contract structure. Operational metrics on inventory turn, stockout risk, and supply chain resilience run through Supply Chain leadership. The cash conversion cycle on the pay side runs through Treasury, with days payable outstanding sitting on the treasurer’s report. The cash conversion cycle on the collect side runs through Revenue Cycle, with days in accounts receivable sitting on a parallel working capital report. The Healthcare Financial Management Association publishes MAP Keys as the industry-standard measurement set for revenue cycle performance (HFMA, 2024b).

The system already has the data to consolidate. The AP file, supplier master, and bank statements record the pay-side activity. The patient accounting system and receivables financing partner statements record the collect-side activity. Payment Yield against the combined base sits across multiple separate reports today, with the supplier-side card rebate yield captured on the Treasury report and the collect-side receivables financing yield captured on the Revenue Cycle working capital report. The two yields read in different units against different denominators on different pages of the CFO’s quarterly review. The reporting architecture that pairs them on the same financial line represents the missing construction, against records the system already maintains.

The non-labor spend base of $750 million distributes across roughly 1,200 active suppliers. GPO-contracted clinical supply carries approximately $310 million across medical-surgical distribution (typically Cardinal Health, McKesson, or Owens and Minor), pharmaceutical distribution, and specialty equipment manufacturers contracted through Vizient, Premier, or HealthTrust. Pharmacy spend subject to 340B Drug Pricing Program economics, where the system participates, carries approximately $90 million at materially discounted acquisition prices relative to wholesale. Non-clinical indirect spend (IT, facilities, professional services, food service, plant operations) carries approximately $280 million outside GPO contracts. Capital equipment in active financing or revenue-share structures carries approximately $70 million of asset value distributed across imaging, surgical robotics, and other revenue-generating capital.

The revenue side runs in parallel. At $1.7 billion in annual revenue and a 52-day median net days in accounts receivable (within the typical industry range against HFMA’s published 30-to-40-day ideal benchmark; HFMA, 2024a), the system carries approximately $242 million in patient AR balance at any given time. The payer mix distributes across commercial insurance (with shorter cycles, typically 30 to 45 days from claim submission), Medicare (14 to 30 days), Medicaid (often beyond 60 days), and patient self-pay (frequently beyond 180 days through patient collections). Revenue Cycle operates the modality stack on the collect side: which receivables get financed and at what discount, which patients enroll in payment plans and on what terms, how point-of-service collections integrate with back-end billing, and which third-party financing programs the system offers.

The operational picture across both sides is detailed. The financial reporting against this picture covers cost, working capital, and operational performance on each side separately. Yield against the same combined base sits across multiple separate reports. Payment Yield consolidates them onto one line.

Why healthcare extends the framework

Healthcare carries three structural features that distinguish it as a measurement site for Payment Economics. The features compress some yield instruments and expand others, and the combination produces a yield architecture distinct from the manufacturing baseline.

Tier 1 architectural compression. The Anti-Kickback Statute at 42 U.S.C. § 1320a-7b prohibits the knowing exchange of remuneration to induce the referral of items or services payable by a federal healthcare program. The Stark Law at 42 U.S.C. § 1395nn governs physician self-referral. The 340B Drug Pricing Program at 42 U.S.C. § 256b creates a separate pricing architecture for covered entities. GPO administrative fees from suppliers run capped at three percent under the safe harbor at 42 C.F.R. § 1001.952(j). Vizient, Premier, and HealthTrust together account for approximately 75 percent of US hospital clinical supply purchasing by volume (Dean, Pierre, Carter, & Bond, 2024). The combined effect is that Capital Return on GPO-contracted clinical supply lands materially below the cross-industry baseline because the GPO administrative fee already absorbs the rebate value the supplier could otherwise return through payment method optimization. Supplier Acceptance on healthcare-eligible spend runs lower than the cross-industry baseline because compliance structuring constrains the form of acceptance the supplier can offer and multi-entity AP fragmentation suppresses the consolidated rate. The Tier 1 yield density at a representative health system therefore runs structurally compressed against the manufacturer Reference Organization baseline (Jasinski, 2026d).

Tier 2 architectural fit on both sides. Tier 2 yield (financing-activated return on capital deployment, introduced in Issue 22; Jasinski, 2026a) operates in healthcare across pay-side and collect-side simultaneously. On the pay side, supply chain finance adoption in healthcare accelerated through the pandemic as systems sought to strengthen supplier resiliency, and the structure continues to grow (Wuttke, Rosenzweig, & Heese, 2019; Inbound Logistics, 2022). Equipment financing tied to revenue performance routes capital equipment through structures where lease terms flex with revenue generation. On the collect side, AR factoring and related receivables financing structures purchase or advance against patient AR at a discount, providing immediate liquidity (Klapper, 2006). Hospital-level adoption of patient AR factoring varies materially across systems; the mechanism is real and operates at industrial scale across the broader healthcare receivables market, with adoption concentrated among staffing firms, specialty practices, and smaller providers, and with variable adoption across regional systems. The combined Tier 2 yield density at a health system that activates instruments on both sides typically runs larger than the Tier 1 yield density on the same spend base, which inverts the architecture relative to the manufacturer baseline where Tier 1 dominates and Tier 2 layers on top.

Dual selection authority across the cash conversion cycle. Treasury holds modality selection authority on the pay side (the decision to launch the virtual card program, the choice between commercial and purchasing card structures, the decision to offer SCF and select the funder, the structure of equipment financing arrangements). Revenue Cycle holds modality selection authority on the collect side (the decision to factor or finance patient AR and select the partner, the structure of patient payment plan offerings, the choice of payment methods accepted on the self-pay side, the integration of point-of-service collections with back-end billing). The two authorities operate on the same capital flow from opposite directions and rarely coordinate. Modality choices made five and ten years ago define the current optimization boundary on each side, which means current optimization works against architectural decisions current teams may not have made. The selection layer remains revisitable at a transition cost, which makes it a periodic governance decision rather than a fixed constraint.

The structural feature that distinguishes healthcare from other operating models is the dual selection authority. Manufacturing in Issue 26 reads through Treasury’s modality stack on the pay side (Jasinski, 2026b) and Procurement’s activation at contract signing (Jasinski, 2026c). Healthcare reads through both of those layers plus Revenue Cycle’s parallel modality selection on the collect side. The framework’s central formula extends without modification: yield density equals Capital Return times Supplier Acceptance, applied to the addressable spend base, with Tier 1 and Tier 2 instruments stacking across the pay side and additional Tier 2 instruments operating on the collect side under Revenue Cycle’s authority. The measurement line reads the full cash conversion cycle rather than the supplier base alone.

How healthcare moves Payment Yield

Issue 2 introduced the formula that organizes the line (Jasinski, 2025):

Payment Yield = Capital Return × Supplier Acceptance

In healthcare, the construction extends across the full cash conversion cycle. Capital Return reads the basis points the system captures from each unit of activated capital flow across Tier 1 instruments (virtual card rebates, ACH float improvements, early payment discount capture) and Tier 2 instruments operating on both the pay side (supply chain finance, equipment financing) and the collect side (AR factoring, receivables-based financing, patient payment plan economics), net of program fees, banking spread, supplier price response, factoring discount, and implementation cost. Supplier Acceptance reads the share of the addressable base (combining the spend side and the collect side under their respective modality stacks) that flows through channels capable of producing the relevant returns, against the actual acceptance rate the system achieves rather than the theoretical eligibility ceiling. On the collect side, the Supplier Acceptance term reads as channel activation: the share of receivables routed through financing, payment-plan, or collections modalities capable of producing measurable economic return. The product is the system’s total yield against its combined capital flow, in basis points against the addressable base.

Control definition. Payment Yield enters the line only when the economic benefit shows up in payment records, contract terms, bank statements, supplier enrollment files, patient accounting records, receivables financing partner statements, or GL-supported cost reduction. Yield that lacks tie-out to one of these source records stays out of the line. This rule keeps the measurement audit-traceable, so Controllership, Treasury, Revenue Cycle, FP&A, and external audit can review it alongside the existing cost-side and working-capital instruments.

Payment Yield in healthcare changes the structure of four categories of capital allocation decision a health system CFO makes regularly.

The first category is the pay-side modality versus collect-side modality tradeoff. The system can deploy a fixed amount of internal capital toward expanding the SCF program for suppliers (extending DPO and capturing buyer-anchored financing yield) or toward accelerating receivables financing on patient AR (reducing DSO and capturing cost-of-capital savings on accelerated cash conversion). Under fragmented measurement, the two moves report against different working capital metrics on different reports. Under paired measurement, both moves report into the Payment Yield line as components of Capital Return, and the comparison runs in a single set of units. The CFO compares two alternatives where both carry quantified financial returns in the same language.

The second category is the GPO-contracted versus non-GPO procurement tradeoff. Procurement evaluates whether to absorb a category under GPO contract structure (capturing scale-based price savings but accepting Capital Return compression on payment method optimization) or to procure outside the GPO (capturing Capital Return at cross-industry norms but forgoing scale-based price advantages). Under fragmented measurement, the price savings sits on a Procurement scorecard and the rebate yield foregone sits on a Treasury report. Under paired measurement, the GPO admin fee absorption appears as a Capital Return compression component and the price savings appears as a separate cost-side benefit, and the procurement leader compares total economic value across the two structures.

The third category is the receivables financing versus internal collections tradeoff. Revenue Cycle evaluates whether to factor or finance a portion of patient AR (accelerating cash conversion and capturing the cost-of-capital savings, net of factoring discount and operational cost) or to carry the AR internally (preserving the full collected amount but absorbing the working capital cost of the carry). The literature on factoring quantifies the economic logic (Klapper, 2006). Under fragmented measurement, the factoring decision reads as a working capital operations choice. Under paired measurement, the cost-of-capital savings reads as Tier 2 yield on the collect side, and the decision becomes a portfolio question.

The fourth category is the supplier-development versus capital-equipment tradeoff, identical in structure to the manufacturing analog from Issue 26 (Jasinski, 2026d). The supplier-development literature (Krause & Ellram, 1997; Krause, Handfield, & Tyler, 2007) extends to healthcare with the additional layer that supplier development in a multi-entity health system also addresses the consolidation work that lifts Supplier Acceptance from the mid-consolidation range to the consolidated range. Under paired measurement, the supplier-development investment carries both a capability return and an activation return, and the CFO compares it against alternative uses of the same capital in shared units.

Segmentation and the activation surface

The manufacturer reference firm in Issue 26 used the Kraljic segmentation as the structural map for Payment Yield activation across the supplier base. Healthcare requires a different segmentation because the structural relationships in the spend base run on different axes. The segmentation that maps to Payment Yield activation in healthcare reads across four spend categories on the pay side, each carrying a distinct yield activation profile, plus a Revenue Cycle activation surface on the collect side.

GPO-contracted clinical supply carries the highest dollar weight on the spend side and the most compressed Capital Return ceiling. The yield activation reads as method specification within GPO contract structure, where the supplier’s available margin to absorb interchange is constrained by the administrative fee already paid to the GPO. The activation moves are coordinated with the GPO contract renewal cycle, with virtual card terms specified at contract renewal rather than negotiated supplier-by-supplier.

340B pharmacy spend, for participating systems, carries a separate pricing architecture under 42 U.S.C. § 256b. Drug acquisition runs at materially discounted prices relative to wholesale, which compresses the dollar base on which any card rebate calculates against pharmacy spend. The yield activation here is narrow on Tier 1 and runs primarily through process efficiency and reconciliation accuracy on the rebate side rather than through margin expansion.

Non-clinical indirect spend sits outside GPO contracts in most systems and retains Capital Return ceilings closer to cross-industry norms. IT, facilities, professional services, food service, and plant operations accept method specification and virtual card activation at acceptance rates comparable to cross-industry baselines. The yield activation here is the largest Tier 1 opportunity on the pay side and the closest analog to the manufacturer reference firm’s leverage quadrant.

Capital equipment routes through financing structures where lease or financing terms can flex with revenue generation from the asset. The yield activation here is Tier 2 on the pay side, with structure varying significantly across asset categories and financing partners. Imaging, surgical robotics, and revenue-generating capital equipment carry the cleanest fit.

Revenue Cycle activation operates on the collect side under Revenue Cycle’s modality selection authority. The activation surface includes patient AR factoring or receivables financing (Tier 2 yield through cost-of-capital savings on accelerated cash conversion), patient payment plan structure (Tier 2 yield through extended-term receivables with quantified collection economics), and the integration between point-of-service collections and back-end billing (process efficiency yield against the same receivables base). The structure varies significantly across systems and is not consistently reported in publicly available industry data.

Case study: a regional health system

The reference health system is modeled on the disciplinary pattern Issue 26 established for manufacturing. Annual revenue is $1.7 billion. Non-labor spend is $750 million. The system operates four hospitals and supporting ambulatory operations. The supplier base distributes across 1,200 active suppliers. The system is GPO-contracted through a major national GPO and is a 340B participant at three of four hospitals. Central AP consolidated three years ago. The virtual card program has been live for two years.

The numbers in this case study come from a model calibrated to typical mid-market regional health system structure, not from a single named system. All yield figures run net of program fees, supplier price response, banking spread, factoring discounts, and implementation cost. Acceptance rates reflect levels a disciplined coordination across Treasury, Procurement, AP, and Revenue Cycle achieves on a coordinated rollout, rather than theoretical eligibility ceilings. Tier 2 penetration rates on the collect side reflect realistic activation among regional systems that have made the selection, recognizing that adoption varies materially across the industry. Firm-specific calibration adjusts the parameters while preserving the structure of the measurement. Read the model skeptically. The case study serves the measurement instrument; the precise dollar contribution serves the demonstration.

Non-clinical indirect: $385,400

The non-clinical indirect spend category carries $280 million in annual spend across IT, facilities, professional services, food service, and plant operations. Current virtual card coverage runs at 24 percent of category volume. The yield measurement reads the remaining 76 percent as a surface for activation.

Procurement, AP, and Treasury run a coordinated supplier enablement program across the category. Acceptance reaches 52 percent of category volume on a twelve-month timeline, reflecting the conversion rate a disciplined enablement program achieves on healthcare non-clinical spend (somewhat below the manufacturer leverage-quadrant analog because of multi-entity AP overhead). Incremental card volume rises by $78 million annualized. The card program earns at a blended 1.65 percent buyer rebate rate, net of program fees and supplier rebate share. The category contributes $385,400 of additional annual yield against the $280 million spend base.

Under fragmented measurement, this conversion reads as an AP operations project. Under paired measurement, it reads as a yield position with a quantified expected return that competes for capital allocation against alternative uses of the same internal effort.

GPO-contracted clinical: $93,100

The GPO-contracted clinical category carries $310 million in annual spend across medical-surgical distribution, pharmaceutical distribution (non-340B), and clinical specialty equipment. Capital Return ceilings on this category run between 0.4 and 0.7 percent because the GPO administrative fee already absorbs a portion of the rebate value the supplier could otherwise return.

Procurement coordinates with the GPO on virtual card terms specification at the next major contract renewal cycle. Acceptance reaches 28 percent of category volume, reflecting the realistic conversion under GPO contract architecture. Incremental card volume rises by $58 million annualized. The card program earns at a blended 0.55 percent buyer rebate rate, net of program fees and the compressed margin available to suppliers under GPO administrative fee structure. The category contributes $93,100 of annual yield.

The number runs materially below the leverage-quadrant analog from Issue 26. Activation discipline holds at the same level. The architectural compression specific to GPO contract structure caps the yield ceiling on this category. The framework reads the compression as an architectural input rather than as a failure of optimization. The yield captured is incremental and net of the GPO admin fee structure already in place.

Capital equipment financing: $174,500

The capital equipment category carries $70 million in active financing or revenue-share structures across imaging, surgical robotics, and other revenue-generating capital assets. Treasury holds modality selection authority for these structures, with terms running across multi-year financing periods.

The system migrates two new asset acquisitions during the year to revenue-share financing structures, replacing direct capital purchase. Combined asset value of the new acquisitions: $11 million. The annual economic return on revenue-share structures, net of financing cost and reflecting the off-balance-sheet and asset-level economic return matching, runs at 2.5 percent on the asset value for the migrated portion, contributing $275,000 annualized over the active financing period. The Year 1 contribution, net of structuring costs and pro-rated activation timing, reads $174,500.

Revenue Cycle AR financing: $307,500

Revenue Cycle holds modality selection authority on the collect side. The system carries $242 million in patient AR balance at any given time. Revenue Cycle has historically operated a mixed approach: a portion of AR runs through internal collections, a portion routes through early-out programs at standard third-party economics, and a portion of high-volume payer AR migrates through a receivables-based financing structure with a specialty firm.

During the year, Revenue Cycle expands the receivables financing program by $50 million annualized in advanced volume, targeting the slow-paying portion of patient AR (specifically Medicaid and self-pay segments that age materially beyond the system’s overall DSO median). The structure runs as a payer-anchored receivables-based financing arrangement rather than full true-sale factoring; the credit risk on the underlying receivable remains substantially with the system, while the financing partner advances against the receivable at a discount calibrated to the segment’s collection profile. The economic value calculation runs through cost-of-capital savings on accelerated cash conversion, net of the financing discount and net of operational cost reduction on the internal collections work the program displaces. The modeled assumptions: an eight percent weighted average cost of capital, a 60-day effective acceleration against the targeted segment’s baseline collection cycle, an effective net financing cost of 70 basis points annualized on the advanced volume (reflecting payer-anchored structuring and netting against displaced internal collections cost). The math: $50 million times 8 percent times (60/365) equals $657,500 in gross cost-of-capital savings, less $50 million times 0.70 percent equals $350,000 in net financing cost, for a net annual yield of $307,500.

This is the most important number in the case study for healthcare specifically. Under fragmented measurement, the receivables financing yield sits on the Revenue Cycle working capital report and never enters the Payment Yield conversation, and the discount fees sit on a different line as cost rather than reading as net yield. Under paired measurement, the program reads as a Tier 2 yield position on the collect side, in the same units and against the same measurement standard as the pay-side yield, with cost-of-capital savings and discount fees netting transparently inside the line. The decision to expand the program competes for capital allocation against pay-side alternatives in shared language. The framework’s universalism shows here: yield generation on the collect side under Revenue Cycle’s authority reconciles into the same line as yield generation on the pay side under Treasury’s authority, because the underlying economics are equivalent regardless of which side of the capital flow the modality operates on.

Reconciliation and double-count control

Issue 23 introduced Payment Yield as a CFO-level measurement aggregating returns across the offices (Jasinski & Yana Mbena, 2026a). Issue 24’s Treasury moves apply at the modality selection layer on the pay side, with the four-move framework extending directly to healthcare’s pay-side categories (Jasinski, 2026b). Issue 25’s Procurement activation at contract signing applies at the GPO renewal cycle in healthcare with one modification: in healthcare, Procurement activates within the GPO contract architecture rather than against direct supplier contracts in most clinical categories (Jasinski, 2026c). Issue 26’s manufacturer case study established the supplier-base activation pattern that healthcare extends to the full cash conversion cycle (Jasinski, 2026d).

The Payment Yield line for the reference health system draws from transaction-level payment records on the pay side, patient accounting records and receivables financing partner statements on the collect side, contract-level activation flags on both sides, and supplier and patient enrollment data, reconciled at the dollar of addressable base. Each dollar receives one primary yield classification at the time of measurement. The pay-side categories (non-clinical indirect, GPO-contracted clinical, capital equipment) sum to the pay-side Payment Yield contribution. The collect-side category (Revenue Cycle AR financing) reports separately as the Tier 2 collect-side contribution. The two sides reconcile against the system’s combined addressable base.

The pay-side activation in this issue draws on the modality selection framework Issue 24 established for Treasury and the contract-level activation framework Issue 25 established for Procurement. The collect-side activation is the structural extension this issue contributes: Revenue Cycle as a parallel modality selection authority operating on the same Payment Yield measurement standard. The categories are additive because they operate on different populations within the system’s combined capital flow. The reconciled total reads as the system’s full year-one Payment Yield contribution.

Stack and full-system reading

The reconciled view stacks as follows. Non-clinical indirect activation contributed $385,400. GPO-contracted clinical activation contributed $93,100. Capital equipment financing migration contributed $174,500. Revenue Cycle AR financing expansion contributed $307,500. The reconciled year-one total reads $960,500.

The total runs against the system’s combined addressable base. On the pay side, $653,000 against $750 million in non-labor spend reads 8.7 basis points against the supplier-side base. On the collect side, $307,500 against $1.7 billion in revenue reads 1.8 basis points against the revenue base, or against the $50 million in advanced volume reads 615 basis points on the activated capital flow. Reading the full system as one capital flow: $960,500 against the combined base of $750 million pay-side plus $50 million collect-side activated volume reads roughly 12 basis points blended.

The number matters because it is reconciled, net, and visible on one line. Before the Payment Yield line consolidated the two-sided architecture, the system captured the pay-side yield through its virtual card program report and the collect-side yield (along with the offsetting financing cost) through a Revenue Cycle working capital report, and the two reports never paired. Under paired measurement, the year-one capital allocation conversation runs across the full cash conversion cycle in shared units. By year three, with the activation programs matured and the modality stacks aligned across Treasury and Revenue Cycle authority, the line crosses 15 to 18 basis points blended at this system scale, and the absolute annual yield runs in the range of $1.4 to $1.8 million against the combined base.

The implication

Manufacturing in Issue 26 completed the supplier-base measurement set, demonstrating that Payment Yield reads beside the existing cost, capability, continuity, and working capital instruments across a four-quadrant supplier base. Healthcare extends the framework. The cash conversion cycle runs on two sides in healthcare, with modality selection authority distributed across Treasury on the pay side and Revenue Cycle on the collect side. Payment Yield in healthcare consolidates the returns from both sides onto a single measurement line, with the formula extending without modification across the combined capital flow.

The structural argument generalizes beyond healthcare. Any vertical where capital flow runs on both sides of the operation under distinct modality selection authorities reads through the same extension. Insurance carriers (premium collection on one side, claims payment on the other), staffing firms (client billing on one side, contractor payment on the other), and financial services firms with both lending and deposit operations carry analogous two-sided structures. The framework is now moving from functional measurement to vertical operating models. The Phase 4 arc takes the framework across additional verticals, each with its own architectural compressions and instrument fit, all reading through the Payment Yield line.

Payment Economics in Practice

Advisory: The Payment Economics Institute works with finance leaders to measure and govern Payment Yield. Healthcare engagements install the return-side line across the full cash conversion cycle, run the activation moves the case study walks through, and align the operating chain across CFO, Treasury, Procurement, AP, and Revenue Cycle onto one Payment Yield measurement. See engagement models →

AP Copilot: The AP platform built for AP teams. AP Copilot turns accounts payable into a profit center through workflow tools designed for the people actually processing payments. The platform achieves 50% virtual card acceptance, 10x the industry average, by making supplier conversion and daily payment work visible, collaborative, and rewarding. 1% of all revenue goes to planting trees. Learn more: apcopilot.com

About The Payment Economics Journal

The Payment Economics Journal examines how organizations measure and capture economic return from payment operations. Published weekly by the Payment Economics Institute. The complete framework lives at payment-economics.org.

Suggested Citation

Jasinski, D. (2026). Payment Economics for Healthcare: The First Two-Sided Payment Yield Model. The Payment Economics Journal, Issue 27. Payment Economics Institute.

Authorship & Editorial

Author: Daniel Jasinski

Editorial Advisor: Jacques Yana Mbena, PhD

References

Centers for Medicare and Medicaid Services. (2025). National Health Expenditures 2024: Highlights. CMS Office of the Actuary. Available here.

Dean, E. B., Pierre, R., Carter, S., & Bond, A. M. (2024). Role of supply chain intermediaries in steering hospital product choice: Group Purchasing Organizations and biosimilars. Health Affairs Scholar, 2(6), qxae067. Available here.

Deloof, M. (2003). Does working capital management affect profitability of Belgian firms? Journal of Business Finance & Accounting, 30(3-4), 573–588. Available here.

Healthcare Financial Management Association. (2024a). 7 KPIs providers should be tracking. HFMA Revenue Cycle KPIs. Available here.

Healthcare Financial Management Association. (2024b). MAP Keys: Industry-standard revenue cycle KPIs. HFMA MAP Initiative. Available here.

Inbound Logistics. (2022). How a global pandemic led to supply chain finance adoption in healthcare. Inbound Logistics. Available here.

Jasinski, D. (2025). Why payment economics is the missing discipline. The Payment Economics Journal, Issue 2. Payment Economics Institute. Read here.

Jasinski, D. (2026a). Embedded capital and Tier 2 yield: How financing-activated returns enter the Payment Yield architecture. The Payment Economics Journal, Issue 22. Payment Economics Institute. Read here.

Jasinski, D. (2026b). Payment economics for Treasury: How Treasury produces financial return from payments. The Payment Economics Journal, Issue 24. Payment Economics Institute. Read here.

Jasinski, D. (2026c). Payment economics for Procurement: How Procurement activates Payment Yield at contract signing. The Payment Economics Journal, Issue 25. Payment Economics Institute. Read here.

Jasinski, D. (2026d). Payment economics for Manufacturing: How Manufacturing completes supplier-base measurement with Payment Yield. The Payment Economics Journal, Issue 26. Payment Economics Institute. Read here.

Jasinski, D., & Yana Mbena, J. (2026a). The CFO measurement problem in enterprise payments: Governing payments as a return-bearing layer. The Payment Economics Journal, Issue 23. Payment Economics Institute. Read here.

Klapper, L. (2006). The role of factoring for financing small and medium enterprises. Journal of Banking & Finance, 30(11), 3111–3130. Available here.

Krause, D. R., & Ellram, L. M. (1997). Critical elements of supplier development: The buying-firm perspective. European Journal of Purchasing & Supply Management, 3(1), 21–31. Available here.

Krause, D. R., Handfield, R. B., & Tyler, B. B. (2007). The relationships between supplier development, commitment, social capital accumulation and performance improvement. Journal of Operations Management, 25(2), 528–545. Available here.

Shin, H. H., & Soenen, L. (1998). Efficiency of working capital management and corporate profitability. Financial Practice and Education, 8(2), 37–45.

Williamson, O. E. (1985). The economic institutions of capitalism: Firms, markets, relational contracting. Free Press.

Wuttke, D. A., Rosenzweig, E. D., & Heese, H. S. (2019). An empirical analysis of supply chain finance adoption. Journal of Operations Management, 65(3), 242–261. Available here.

42 U.S.C. § 1320a-7b. Criminal penalties for acts involving Federal health care programs (Anti-Kickback Statute).

42 U.S.C. § 1395nn. Limitation on certain physician referrals (Stark Law).

42 U.S.C. § 256b. Limitation on prices of drugs purchased by covered entities (340B Drug Pricing Program).

42 C.F.R. § 1001.952(j). Group purchasing organizations safe harbor.